These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 31924739

  • 1. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G, Schmitz S, El Baroudi M, Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D, Machiels JP.
    Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
    [Abstract] [Full Text] [Related]

  • 2. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
    van Caloen G, Machiels JP.
    Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
    [Abstract] [Full Text] [Related]

  • 7. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Oncotarget; 2016 Mar 22; 7(12):14803-13. PubMed ID: 26909611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D, Sun X, Zhang X, Cao J.
    Biomed Res Int; 2020 Mar 22; 2020():9525207. PubMed ID: 32626773
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
    Liu Y, Zhao R, Fang S, Li Q, Jin Y, Liu B.
    Fundam Clin Pharmacol; 2021 Feb 22; 35(1):156-164. PubMed ID: 32446293
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
    Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP.
    Clin Cancer Res; 2017 Jun 01; 23(11):2856-2868. PubMed ID: 27986745
    [Abstract] [Full Text] [Related]

  • 19. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An In Vitro Study.
    Tai TS, Lin PM, Wu CF, Hung SK, Huang CI, Wang CC, Su YC.
    Anticancer Res; 2019 Feb 01; 39(2):713-720. PubMed ID: 30711949
    [Abstract] [Full Text] [Related]

  • 20. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.
    J Neurooncol; 2019 Sep 01; 144(3):563-572. PubMed ID: 31399936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.